SynsoryBio: Therapeutics that sense-and-respond to disease

TL;DR

At SynsoryBio, we engineer "if-then" conditional logic into protein medicines, meaning only if the protein drug senses a disease marker, then it turns on. We are applying this technology to clinically tested, but highly toxic cancer immunotherapies to make them safer and more effective.

Who we are/Team:

SynsoryBio was founded by brother scientists, Elliot and Nathan, who both hold PhDs in biomedical engineering. The founders gained expertise in synthetic biology at Boston University, Harvard Medical School, and industrial biotech, where they authored numerous high-impact journal publications and are inventors on several patent filings. SynsoryBio harnesses this expertise to create next-generation therapeutics that understand where they are in the body and only act at the site of disease.

The Problem:

The most potent therapeutics suffer from safety issues and dose limitations, impeding their development and overall efficacy. This isn’t surprising because most therapeutics are delivered systemically and are active throughout the body even though the underlying disease is localized to a certain tissue. For example, immunotherapies to treat cancer show great promise but usually exhibit dose limitations, especially in combination, which prevents the development of potent immune stimulators and/or mitigates clinical efficacy.

The Synsory Solution:

We are developing next-generation protein therapeutics that have synthetic sensing functions so that they know where they are in the body and only act at disease tissue. Our approach is highly flexible, allowing us to design protein therapeutics that conditionally activate upon sensing virtually any specified biomolecule.

Our ask:

-If you know any immunologists or oncologists, we would love to connect with them!

-Interested in partnering? Please reach out!

Connect with us, info@synsorybio.com